**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 6000**

**Columns: TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (3): Inflammatory bowel disease

Venous thrombosis and prothrombotic factors in inflammatory bowel disease

Magro F *et al*.Venous thrombosis and IBD

Fernando Magro, João-Bruno Soares, Dália Fernandes

**Fernando Magro,** Gastroenterology Department, Centro Hospitalar São João, Porto 4200-319, Portugal

**Fernando Magro,** Institute of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto 4200-319, Portugal

**Fernando Magro,** IBMC, Institute for Molecular and Cell Biology, University of Porto, Porto 4150-180, Portugal

**João-Bruno Soares, Dália Fernandes**, Gastroenterology Department, Hospital de Braga, Braga 4710-243, Portugal

**João-Bruno Soares, Dália Fernandes**, Dália Fernandes, Gastroenterology Department, Centro Hospitalar da Cova da Beira, Covilhã 6200-251, Portugal

**Author contributions:** Magro F and Soares JB contributed equally to this work; Magro F and Soares JB contributed to the conception and design, acquisition, analysis and interpretation of data, drafting and revising of the article for important intellectual content and final approval of the version to be published; Fernandes D contributed to the acquisition, analysis and interpretation of data, drafting of the article and final approval of the version to be published.

**Correspondence to: Fernando Magro, MD, PhD,** Institute of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal. fm@med.up.pt

**Telephone**: + 351-22-5513600  **Fax**: +351-22-5513601

**Received:** September 29, 2013  **Revised:** January 12, 2014

**Accepted:** March 12, 2014

**Published online:**

**Abstract**

Patients with inflammatory bowel disease (IBD) may have an increased risk of venous thrombosis (VTE). PubMed, ISI Web of Knowledge and Scopus were searched to identify studies investigating the risk of VTE and the prevalence of acquired and genetic VTE risk factors and prothrombotic abnormalities in IBD. Overall, IBD patients have a two- to fourfold increased risk of VTE compared with healthy controls, with an overall incidence rate of 1-8%. The majority of studies did not show significant differences in the risk of VTE between CD and UC. Several acquired factors are responsible for the increased risk of VTE in IBD: inflammatory activity, hospitalisation, surgery, pregnancy, disease phenotype (*e.g*., fistulising disease, colonic involvement and extensive involvement) and drug therapy (mainly steroids). There is also convincing evidence from basic science and from clinical and epidemiological studies that IBD is associated with several prothrombotic abnormalities, including initiation of the coagulation system, downregulation of natural anticoagulant mechanisms, impairment of fibrinolysis, increased platelet count and reactivity and dysfunction of the endothelium. Classical genetic alterations are not generally found more often in IBD patients than in non-IBD patients, suggesting that genetics does not explain the greater risk of VTE in these patients. IBD VTE may have clinical specificities, namely an earlier first episode of VTE in life, high recurrence rate, decreased efficacy of some drugs in preventing further episodes and poor prognosis. Clinicians should be aware of these risks, and adequate prophylactic actions should be taken in patients who have disease activity, are hospitalised, are submitted to surgery or are undergoing treatment.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Acquired; Genetic; Prothrombotic; Venous thrombosis; Risk of venous thrombosis

**Core tip:** In inflammatory bowel disease (IBD), there is an increased risk of venous thrombosis (VTE) due to inflammatory activity, hospitalisation, surgery, pregnancy, disease phenotype and drug therapy. Classical genetic alterations are not generally found more often in IBD patients than in non-IBD patients, suggesting that genetics does not explain the greater risk of VTE in these patients. IBD VTE may have clinical specificities, namely an earlier first episode of VTE in life, high recurrence rate, decreased efficacy of some drugs in preventing further episodes and poor prognosis.

Magro F, Soares JB, Fernandes D. Venous thrombosis and prothrombotic factors in inflammatory bowel disease.

**Available from: URL:**

**DOI:**

**INTRODUCTION**

The possible association between inflammatory bowel disease (IBD) and venous thrombosis (VTE) was first reported in 1936 by Bargen *et al*[[1](#_ENREF_1)], who described 18 patients with thromboembolic disease (predominantly venous) from among more than 1000 patients treated for IBD at the Mayo Clinic. Since that time, several publications have suggested that patients with IBD have an increased risk of VTE, including deep venous thrombosis (DVT), pulmonary emboli (PE), portal vein thrombosis (PVT), cerebral venous sinus thrombosis, Budd Chiari syndrome and retinal vein thrombosis[[2-5](#_ENREF_2)]. The overall incidence rate of VTE in IBD patients has been estimated to be 1%–8%, although necropsy studies report an incidence of 39-41%[[2-5](#_ENREF_2)]. One systematic review[[4](#_ENREF_4)] and one meta-analysis[[3](#_ENREF_3)] showed a higher VTE risk in IBD patients, even after correction for known prothrombotic factors such as smoking and obesity[[3](#_ENREF_3)]. Nevertheless, other studies, such as that of Grip *et al*[[6](#_ENREF_6)], show a similar risk between IBD and the background population. However, in that report, where the incidence of VTE in the IBD cohort (0.15% per year) was comparable with that of the background population, the differences in age between the groups could have affected the conclusions[[6](#_ENREF_6)].

It is important to stress that most of the evaluated studies were retrospective. When the IBD population was compared with other patients or healthy controls, most of the classical prothrombotic risks were not assessed, and therefore a bias could have been present. Therefore, the aim of this review was to assess the risk of VTE and the prevalence of acquired and genetic VTE risk factors and prothrombotic abnormalities in IBD.

**SEARCH STRATEGY**

A systematic review was conducted on published articles that assessed the risk of VTE and the prevalence of acquired and genetic VTE risk factors and prothrombotic abnormalities in IBD through a literature search of PubMed, ISI Web of Knowledge and Scopus. This search was performed in September 2013 using the following medical terms: “venous thrombosis IBD”, “acquired venous thrombosis risk factor IBD”, “genetic venous thrombosis risk factor IBD”, “coagulation IBD”, “fibrinolysis IBD”, “platelets IBD” and “endothelium IBD”. Additionally, a comprehensive search of reference lists of all review articles and original papers achieved by this method was performed to identify additional reports that could be included in the final analysis. Potential studies were initially screened by title and abstract. Potential exclusion criteria to reduce the risk of bias and unnecessary observations included case reports on single patients, book chapters and studies exclusively on arterial thrombosis. A total of 207 articles were studied to construct this review.

**RISK OF VTE IN IBD**

A summary of the controlled studies comparing the risk of VTE in IBD patients with the risk of VTE in non-IBD patients is presented in Table 1.

***General risk***

In one of the earliest studies evaluating the incidence of VTE in IBD patients, 61 out of 7199 patients (0.84%) developed VTE during an 11-year period from January 1970 to December 1980 at the Mayo Clinic, with similar rates of VTE observed in patients with Crohn’s disease (CD) and ulcerative colitis (UC)[[7](#_ENREF_7)]. In 2001, Bernstein *et al*[[8](#_ENREF_8)] published the first study on the risk of VTE in IBD in a large population-based study using health administrative data from the province of Manitoba, Canada, in which they applied validated case ascertainment definitions of CD and UC (Table 1). The incidence rate for VTE in IBD patients was 45.6 per 10000 persons-year of follow-up, and IBD patients were 3.5 times more likely to develop VTE than the controls. Similar rates of VTE were observed in CD and UC and in males and females. The highest rates of VTE were observed among patients over 60 years old; however, the highest incidence rate ratio (IRR) for VTE was among patients younger than 40 years old (IRR = 6.02, 95%CI: 3.92 – 9.12). In 2004, Miehsler *et al*[[9](#_ENREF_9)] compared the risk of VTE in patients with IBD and other chronic inflammatory diseases (rheumatoid arthritis and coeliac disease) with matched controls (Table 1). The subjects with IBD had a significantly higher risk of VTE compared with the matched controls [prevalence: 6.15% *vs* 1.62%; odds ratio (OR) = 3.6, 95%CI: 1.7–7.8], whereas the subjects with rheumatoid arthritis or coeliac disease had a risk of VTE similar to that of the controls. In 2007, the risk of VTE among 17 chronic illnesses was evaluated (Table 1)[[10](#_ENREF_10)]. The relative risk (RR) of VTE was nearly twofold higher in IBD patients than in the matched controls (OR = 1.84, 95%CI: 1.29-2.63), with only cancer and heart failure carrying a greater risk of VTE than IBD.

***IBD, activity, hospitalisation and surgery***

Some studies have shown that the risk of VTE may be higher in UC than in CD [[11](#_ENREF_11), [12](#_ENREF_12)], with other studies showing the opposite[[13](#_ENREF_13)]; however, the majority of studies did not show significant differences in the risk of VTE between CD and UC[[3](#_ENREF_3), [4](#_ENREF_4), [8](#_ENREF_8), [14](#_ENREF_14), [15](#_ENREF_15)]. A recent meta-analysis showed similar risks in patients with UC (RR = 2.57, 95%CI: 2.02–3.28; *n =* 6 studies) and CD (RR = 2.12, 95% = CI 1.40–3.20; *n =* 5 studies)[[3](#_ENREF_3)].

Several studies reported IBD activity in 45 to 90% of patients at the time of VTE diagnosis[[8](#_ENREF_8), [9](#_ENREF_9), [16-18](#_ENREF_16)]. The association of VTE and IBD flares was assessed using a large primary care database from the United Kingdom (Table 1)[[19](#_ENREF_19)]. According to the data from this assessment, the risk of VTE was increased most prominently during a flare of IBD [hazard risk (HR) = 8.4, 95%CI: 5.5–12.8], compared with periods of chronic activity (HR = 6.5, 95%CI: 4.6–9.2) and periods of clinical remission (HR = 2.1, 95%CI: 1.6–2.9). The RR at the time of a flare, compared with a matched control, was higher during non-hospitalised periods (HR = 15.8, 95%CI: 9.8–25.5 *vs* HR = 3.2, 95%CI: 1.7–6.3). However, this finding must be interpreted with caution because the lower RR during hospitalised periods is related to a higher absolute risk (37.5 *vs* 6.4 per 1000 persons-years), and the treatment with corticosteroids in patients with active disease may also be an additional risk factor for the development of VTE. Moreover, the use of VTE prophylaxis in hospitalised patients can also contribute to a lower RR of VTE during hospitalisation. Bernstein *et al*[[20](#_ENREF_20)] showed higher VTE rates in hospitalised IBD patients than in non-IBD hospitalised patients regardless of age (Table 1). IBD patients who were younger than 50 years had a higher RR than those who were older than 50 years (RR = 1.57, 95%CI: 1.42-1.72 *vs* RR = 1.30, 95% CI: 1.23-1.37)[[20](#_ENREF_20)]. Nguyen *et al*[[12](#_ENREF_12)] compared the risk of VTE between hospitalised IBD patients and randomly selected hospitalised non-IBD patients (Table 1) and reported that IBD patients had an adjusted 1.7-fold [adjusted OR (aOR) = 1.66, 95%CI: 1.33-2.06] increased rate of VTE compared with non-IBD patients. In 2011, three studies were published showing a 1.1- to 3.1-fold higher risk of VTE in hospitalised IBD patients (Table 1)[[11](#_ENREF_11), [21](#_ENREF_21), [22](#_ENREF_22)].

The risk of VTE in IBD was also evaluated in the surgical setting. Merrill *et al*[[23](#_ENREF_23)] compared the risk of VTE between patients with IBD and patients without IBD who underwent surgery in 211 hospitals participating in the American College of Surgeons National Surgical Quality Improvement Program (Table 1). The incidence of VTE was 2.5% in IBD patients (*n =* 57) *vs* 1.0% (*n =* 2608) in the controls. IBD remained a significant predictor of VTE after multivariate adjustment (OR = 2.03, 95%CI: 1.52-2.70). Another interesting finding of this study was the observation that the risk persisted even when procedures on small and large bowels were excluded, with IBD patients undergoing non-intestinal procedures having a 4.45-fold increased risk of VTE compared with non-IBD patients. Furthermore, in a large cohort of surgical IBD patients, bleeding disorders, steroid use, anaesthesia time, emergency surgery, haematocrit < 37%, malnutrition and functional status were identified as potentially modifiable risk factors for postoperative VTE in IBD patients[[24](#_ENREF_24)].

***Pregnancy***

The risk of VTE in IBD was also evaluated during pregnancy and puerperium. According to the Nguyen *et al*[[14](#_ENREF_14)] study, based on nationwide inpatient sample data (database containing discharge abstracts from 1054 hospitals in the United States), the aOR of VTE was substantially higher in women with CD (aOR = 6.12; 95%CI: 2.91-12.9) and UC (aOR = 8.44, 95%CI: 3.71-19.2) compared with the non-IBD obstetric population, and this increased risk was independent of whether the women underwent a caesarean section (Table 1). A similar study conducted by Bröms *et al*[[15](#_ENREF_15)] in Sweden also showed an increased risk of VTE in pregnant IBD patients compared with non-IBD pregnant patients but showed a lower odds ratio (aOR = 2.65, 95%CI: 0.65–10.1 for CD; aOR = 3.78, 95%CI: 1.52–9.38 for UC) (Table 1). For women with UC, the increased risk of VTE seemed to be highest during pregnancy and not during puerperium in the general population of women giving birth.

***IBD-phenotype risk factors***

Several IBD-phenotype risk factors have been shown to affect the risk of VTE. Nguyen *et al*[[12](#_ENREF_12)] reported that fistulising disease was independently associated with a greater VTE risk (OR = 1.39, 95%CI: 1.13-1.70). Colonic involvement in CD patients or extensive disease in UC patients was also associated with an increased VTE risk. A study by Solem *et al*[[17](#_ENREF_17)] showed that CD patients with VTE typically had colonic disease involvement (ileocolonic in 56% and colonic in 23%), and most UC patients with VTE (76%) had pancolonic disease. Nguyen *et al*[[12](#_ENREF_12)] found a higher risk of VTE in CD patients with colonic-only disease that was 40% higher than the risk of VTE in those with small bowel-only disease. In UC patients, 25% experienced VTE after proctocolectomy, and VTE recurrence rates were not improved by proctocolectomy[[17](#_ENREF_17)].

***IBD-nonspecific acquired risk factors***

In IBD, several nonspecific acquired risk factors, other than those previously discussed, often increase the risk of VTE, such as oral contraceptive/hormone substitution use, smoking and drug therapy (Table 2). In most studies, at least one of the known clinical risk factors for VTE was present in approximately 20-50% of IBD patients with VTE at the time a TE occurred[[9](#_ENREF_9), [16](#_ENREF_16), [18](#_ENREF_18), [25](#_ENREF_25)]. Approximately 30% of these patients may have two or more risk factors[[9](#_ENREF_9)].

**PROTHROMBOTIC ABNORMALITIES IN IBD**

***Impact of inflammation on coagulation***

Although the causes of the increased risk of VTE in IBD are not yet completely understood, most studies suggest that this risk is largely dependent on the biological and biochemical effects exerted by the activation of the inflammatory pathways (*e.g*., cells and cytokines) in the haemostatic system. In fact, there is now convincing evidence from clinical, epidemiological and experimental studies that inflammation and VTE are related[[5](#_ENREF_5), [26-28](#_ENREF_26)]. Many inflammatory diseases other than IBD, such as systemic lupus erythaematosus, Behçet’s disease, polyarteritis nodosa and polymyositis/dermatomyositis, have been associated with an increased risk of VTE in several clinical and epidemiological studies[[5](#_ENREF_5), [26-28](#_ENREF_26)]. This association appears to be the strongest when the time between the exposure and the outcome is short, *e.g*., when the inflammatory disease was experienced recently or, more specifically, in the active stage of an inflammatory disease (flare-up)[[5](#_ENREF_5), [26-28](#_ENREF_26)]. In many inflammatory diseases, such as systemic lupus erythaematosus and Behçet’s disease, VTE may be part of the presentation of those diseases. VTE in IBD may complicate the differential diagnosis with other inflammatory diseases that may also lead to VTE and intestinal inflammation, such as Behçet’s disease.

The impact of inflammation on coagulation has been confirmed by several experimental studies showing that inflammatory mechanisms shift the haemostatic balance to favour the activation of coagulation and, in the extremes, VTE[[27](#_ENREF_27)]. Inflammatory mediators can initiate the coagulation system, downregulate natural anticoagulant mechanisms, impair fibrinolysis, elevate the platelet count and reactivity and lead to the dysfunction of the endothelium[[27](#_ENREF_27)].

Tumour necrosis factor-alpha (TNF-α) and CD40 ligand (CD40L), two inflammatory cytokines, and C-reactive protein (CRP), a liver-synthesised acute phase protein, have been shown to induce the expression of tissue factor (TF) on the cell surface of leucocytes[[29-31](#_ENREF_29)]. Interleukin (IL)-6, an inflammatory cytokine, and TNF-α have been shown to lead to thrombin generation[[32](#_ENREF_32), [33](#_ENREF_33)]. Of the natural anticoagulant pathways, the protein C pathway and heparin-antithrombin pathway have been shown to be downregulated by IL-1β and TNF-α[[34](#_ENREF_34), [35](#_ENREF_35)], whereas the tissue factor pathway inhibitor (TFPI) has been shown to be inhibited by CRP[[36](#_ENREF_36)]. There is also evidence that CRP increases the expression of plasminogen activator inhibitor type 1 (PAI-1) and decreases the expression of tissue plasminogen activator (t-PA)[[37](#_ENREF_37), [38](#_ENREF_38)].

Inflammatory mediators, such as IL-6, increase platelet production. The newly formed platelets appear to be more thrombogenic. For example, the newly formed platelets activate at lower concentrations of thrombin[[39](#_ENREF_39)]. Thus, both the platelet count and platelet reactivity are increased in response to inflammatory mediators.

Some authors have proposed the term “endothelial stunning” for the endothelial dysfunction/activation that may be induced by inflammatory cytokines and may thus play a key-role in the association between inflammation and VTE[[40](#_ENREF_40)]. For example, CRP has been shown to induce the release of von Willebrand factor (vWF)[[41](#_ENREF_41)] and to reduce the production of nitric oxide (NO) by endothelial cells[[42](#_ENREF_42)].

As discussed above, in general for inflammatory diseases, there is also convincing evidence from basic science as well as clinical and epidemiological studies that IBD is associated with several prothrombotic abnormalities, including the initiation of the coagulation system, downregulation of natural anticoagulant mechanisms, impairment of fibrinolysis, increase in the platelet count and reactivity and dysfunction of the endothelium (Table 3)[[43-45](#_ENREF_43)].

The mechanisms underlying IBD-associated prothrombotic abnormalities have been the subject of recent experimental and clinical studies. For example, Yoshida *et al*[[46](#_ENREF_46), [47](#_ENREF_47)] showed that TNF-α and IL-1β are both implicated in the enhanced extra-intestinal thrombosis that accompanies experimental colitis [mice with dextran sodium sulphate (DSS)-induced colitis]. The authors noted that exogenous TNF-α and IL-1β enhanced thrombosis in the arterioles of control mice and that the enhanced thrombus formation in the arterioles of mice with DSS-induced colitis was significantly attenuated in wild-type colitic mice treated with TNF-α or IL-1β blocking antibodies and in colitic mice deficient for the TNF-α receptor or the IL-1 receptor. The IL-6 concentrations were positively correlated with disease activity and thrombocytosis in patients with UC[[48](#_ENREF_48)]. Taken together, these data suggest that inflammatory cytokines such as TNF-α, IL-1β and IL-6 may play an important role in the inflammation-mediated risk of VTE in IBD.

***Abnormalities of haemostasis associated with IBD***

**Abnormalities of coagulation:** Quantitative alterations in key sites of the coagulation cascade that favour clot formation occur in patients with IBD[[44](#_ENREF_44)]. These alterations include the elevation of circulating microparticles (including TF-rich microparticles)[[49](#_ENREF_49), [50](#_ENREF_50)], factor VIIa[[51](#_ENREF_51)], factors XIIa and XIa[[52](#_ENREF_52)], factors Xa and Va[[52](#_ENREF_52), [53](#_ENREF_53)], prothrombin[[7](#_ENREF_7), [54-56](#_ENREF_54)] and fibrinogen[[56](#_ENREF_56), [57](#_ENREF_57)]. The levels of antithrombin (AT) are significantly lower in the plasma of patients with IBD[[56](#_ENREF_56), [58](#_ENREF_58)]. Reports on protein C and S deficiency in IBD are conflicting[[48](#_ENREF_48), [59-61](#_ENREF_59)]. There is also a significantly lower expression of endothelial protein C receptor (EPCR) and thrombomodulin (TM), which impairs protein C activation leading to lower effective protein C activity[[62](#_ENREF_62)]. TFPI levels were also shown to be reduced in patients with IBD[[63](#_ENREF_63), [64](#_ENREF_64)]. Alterations suggestive of the activation of coagulation have also been reported in IBD. These include elevated prothrombin fragment 1+2 (prothrombin F1+2), thrombin-antithrombin (TAT) complexes, fibrinopeptide A (FPA) and B (FPB)[[7](#_ENREF_7), [54-56](#_ENREF_54)] and decreased factor XIII levels[[57](#_ENREF_57), [65](#_ENREF_65)].

IBD treatment was also found to influence coagulation abnormalities associated with IBD. For example, the treatment with infliximab induced a significant decrease in the amounts of circulating microparticles in IBD patients[[49](#_ENREF_49)].

**Abnormalities of fibrinolysis: T**he circulating concentration of factors involved in the lysis of clots also favours thrombosis in IBD. The plasma levels of t-PA are significantly lower in IBD patients than these levels in the general population[[66](#_ENREF_66), [67](#_ENREF_67)]. There is also a significant absolute increase in urokinase-type plasminogen activator (u-PA) activity and a decrease in t-PA activity in the inflamed mucosa of IBD patients compared with the control group[[66](#_ENREF_66)]. Two proteins that inhibit fibrinolysis, PAI-1[[66](#_ENREF_66)] and thrombin-activatable fibrinolysis inhibitor (TAFI)[[68](#_ENREF_68)], were found in higher concentrations in the plasma of IBD patients. Increasing levels of D-dimer, a fibrin degradation product, were also found in IBD, mainly in patients with active disease[[58](#_ENREF_58)]. As D-dimer is generated from cross-linked fibrin, but not from fibrinogen, an elevated plasma concentration of D-dimer indicates recent or ongoing intravascular blood coagulation.

**Abnormalities of platelets:** In patients with IBD, there are often increased circulating platelet numbers and platelet and leukocyte-platelet aggregates (PLAs)[[69](#_ENREF_69)]. Greater platelet aggregation has also been demonstrated in the mesenteric vasculature compared with non-IBD controls, supporting the hypothesis that platelet activity is stimulated in the mesenteric microcirculation[[70](#_ENREF_70)]. Indeed, spontaneous platelet aggregation or platelet hypersensitivity to low levels of aggregating agents occurs in nearly one-half of patients with IBD[[71](#_ENREF_71)] and appears to be independent of the disease activity[[57](#_ENREF_57), [71](#_ENREF_71)]. Such platelet hyperactivation is mediated at least partly by the CD40–CD40L pathway, a key regulator and amplifier of immune-inflammatory reactivity and inducer of TF, which initiates the extrinsic coagulation pathway. Evidence for the involvement of CD40L includes a markedly elevated expression of CD40L protein by platelets from patients with IBD and the release of larger amounts of soluble CD40L into the plasma, leading to an approximately 15-fold increase in the CD40L plasma levels[[72](#_ENREF_72), [73](#_ENREF_73)]. There are also elevated levels of CD40L in the mucosa that appear to be proportional to the degree of inflammation[[72](#_ENREF_72), [74](#_ENREF_74)]. The activation of platelets in IBD may also be mediated by P-selectin. IBD patients have been reported to have more platelets expressing P-selectin (marker of platelet activation) than healthy controls[[69](#_ENREF_69)]. In the DSS model of murine colonic inflammation, colonic inflammation has been reported be associated with an increased number of circulating activated platelets, along with the formation of PLAs, which can be inhibited by selectin blockade with fucoidin[[75](#_ENREF_75)].

The IBD treatment may influence platelet abnormalities associated with IBD. Infliximab significantly reduced plasma-soluble CD40L levels and eliminated CD40 from mucosal microvessels[[76](#_ENREF_76)], whereas IBD patients on thiopurines had fewer PLAs than those not taking them[[69](#_ENREF_69)]. These findings suggest that IBD treatment may influence platelet abnormalities associated with IBD.

**Abnormalities of endothelium:** Endothelial dysfunction has been clearly demonstrated in IBD patients and involves several aspects of endothelium biochemical physiology[[77](#_ENREF_77)]. In particular, such dysfunction involves an alteration in the NO and reactive oxygen species (ROS) balance, which occurs when the endothelium fails to generate NO, a potent vasodilator and anti-aggregating agent, and instead forms elevated levels of superoxide anion[[78](#_ENREF_78)]. Decreased NO generation may result from an acquired deficient transcription of nitric oxide synthase 2 (NOS2) in chronically inflamed IBD endothelium[[79](#_ENREF_79)] and from the induction, by many inflammatory cytokines (*e.g*., IL-2 and TNF-α), of the enzyme arginase, which competes with NOS[[80](#_ENREF_80)]. The increased production of ROS in the inflamed endothelium may also contribute to oxidative stress in vWF molecules, which become unresponsive to proteolysis by ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), leading to the accumulation of ultra-large vWF multimers[[81](#_ENREF_81)]. The latter are the most haemostatically active forms of vWF and, by favouring platelet adhesion and aggregation, may contribute to microvascular thrombosis in IBD. Increased levels of vWF were reported in IBD patients, especially in those with active disease[[58](#_ENREF_58), [82](#_ENREF_82)].

***Thrombophilia and IBD***

**Acquired risk factors:** Antiphospholipid antibodies (APLA) and hyperhomocysteinaemia are two acquired thrombophilias associated with arterial and venous thrombosis. APLA are a group of prothrombotic antibodies directed against plasma proteins that are bound to anionic phospholipids. Patients with APLA may present with venous or arterial thrombosis, recurrent foetal loss and/or thrombocytopaenia. The disorder may be primary or may be associated with pregnancy or with inflammatory, post infectious and other disease states. This group of antibodies includes anti-cardiolipin (aCL), anti-β2-glycoprotein 1 (b2-GPI) and lupus anticoagulants, each of which requires specific testing. Available studies in IBD vary in the assessment of different antibodies, types of IBD and disease activity level; therefore, the true prevalence of APLA in IBD patients remains unclear. The prevalence of aCL antibodies in IBD patients is higher than in the control population, with an average incidence of 20–30%, but the association with thrombosis in IBD patients is less clear[[83](#_ENREF_83)]. Similarly, the levels of antibodies against b2-GPI, the cofactor that mediates the binding of aCL antibodies to cardiolipin and a more specific measure of the risk associated with thrombosis, has been detected in 9% of patients with IBD compared with its absence in healthy controls[[84](#_ENREF_84)]. Lupus anticoagulants were not detected in a small series of 16 patients with CD[[85](#_ENREF_85)]. The levels of aCL antibodies and anti-b2-GPI antibodies and of lupus anticoagulants were similar in a population of IBD patients with and without current or past VTE events[[84](#_ENREF_84), [86](#_ENREF_86)]. One of the causes of the appearance of APLA in IBD may be anti-TNF-α therapy because this therapy has been associated with the development of APLA[[87](#_ENREF_87), [88](#_ENREF_88)].

Hyperhomocysteinaemia may be both a genetic and acquired abnormality. The most common genetic defect is homozygosity for a thermolabile mutant of the enzyme methylenetetrahydrofolate reductase (MTHFR)[[89](#_ENREF_89)]. Plasma homocysteine concentrations can also be increased by deficiencies in vitamin B6, B12 or folic acid (dietary, genetic or drug-associated)[[90](#_ENREF_90)]. Hyperhomocysteinaemia is an independent risk factor for atherosclerotic vascular disease, with the risk increasing in a graded fashion with increasing plasma homocysteine concentrations[[91](#_ENREF_91), [92](#_ENREF_92)]. Hyperhomocysteinaemia has also been associated with an increased risk of VTE[[93](#_ENREF_93), [94](#_ENREF_94)]. Reducing levels of homocysteine with B vitamin supplements, however, has not resulted in a reduction in the incidence of recurrent VTE or arterial thrombotic complications[[95](#_ENREF_95), [96](#_ENREF_96)]. The association of folate deficiency and hyperhomocysteinaemia has been evaluated in IBD patients. One study reported elevated serum homocysteine and low folate in 63 patients with IBD, but these levels were not observed in 183 matched controls without thrombotic complications[[97](#_ENREF_97)]. In a small study, fasting homocysteine levels in IBD patients with a history of arterial or venous thrombosis tended to be higher (although not significantly) than in IBD controls[[98](#_ENREF_98)]. Recently, Oussalah *et al*[[99](#_ENREF_99)] conducted a systematic review and meta-analysis to evaluate the association between homocysteine metabolism and IBD and the association between hyperhomocysteinaemia and thrombosis in IBD. The mean plasma homocysteine level was significantly higher in IBD patients compared with the controls. The mean plasma homocysteine level did not differ between patients with UC and CD. The risk of hyperhomocysteinaemia was significantly higher in IBD patients compared with controls (OR = 4.65, 95%CI: 3.04-7.09). The risk of hyperhomocysteinaemia was not higher among IBD patients who experienced thromboembolic complications (OR = 1.97, 95%CI: 0.83-4.67), suggesting that hyperhomocysteinaemia may not be a major contributor to VTE in IBD. Medication-associated folate deficiency (*e.g*., methotrexate or sulfasalazine) may be the most common explanation for hyperhomocysteinaemia in IBD patients, although deficiencies in vitamin B6 and B12 and a MTHFR mutation may also play a role (see below). Taken together, the current data do not support a major role for APLA or hyperhomocysteinaemia in IBD-associated VTE, but studies with a higher number of patients and a prospective design are needed.

**Inherited risk factors:** A summary of controlled studies on the prevalence of inherited thrombophilias in IBD is presented in Table 3. The rate of inherited thrombophilias in patients with IBD and VTE is estimated to be 15%-30%, which is similar to the rate in non-IBD patients and VTE in most studies[[6](#_ENREF_6), [17](#_ENREF_17), [25](#_ENREF_25), [98](#_ENREF_98), [100-104](#_ENREF_100)], although one study has reported a lower rate of inherited thrombophilias in patients with IBD and VTE[[105](#_ENREF_105)]. Data comparing the prevalence of inherited thrombophilias in the overall IBD population and in the general population are conflicting. Although some cohorts reported a higher prevalence in the overall IBD population[[106-109](#_ENREF_106)], most reported a similar prevalence[[6](#_ENREF_6), [16](#_ENREF_16), [61](#_ENREF_61), [102-104](#_ENREF_102), [109-121](#_ENREF_109)]. These data suggest that the role of inherited thrombophilias in VTE in IBD patients is similar to that in the general population.

The most prevalent thrombophilia reported in IBD patients is factor V Leiden. Other genetic variants that have been found in IBD patients include the prothrombin G20210A mutation, deficiencies in protein C, protein S and antithrombin, the PAI-1 4G mutation, the factor XII val34leu mutation and the MTHFR C677T mutation (Tables 2 and 3). Factor V Leiden increases the risk of thrombosis five- to eightfold for heterozygous carriers and 50- to 80-fold for homozygous carriers[[122](#_ENREF_122)]. A similar frequency of factor V Leiden was reported in IBD patients with thrombosis compared with thrombotic controls[[6](#_ENREF_6), [102](#_ENREF_102), [104](#_ENREF_104)] and in the overall IBD population compared with the general population[[61](#_ENREF_61), [109](#_ENREF_109)]. However, the prevalence of factor V Leiden in thrombotic IBD patients has been shown to be significantly higher than that in IBD patients without thrombosis, suggesting that factor V Leiden, when present, increases the risk of IBD-associated VTE[[101](#_ENREF_101), [102](#_ENREF_102)]. Two recent meta-analyses confirmed this conclusion. In the meta-analysis of Zhong *et al*[[123](#_ENREF_123)], the OR of VTE in IBD patients with factor V Leiden was higher than in IBD patients (OR = 4.00, 95%CI: 2.04-7.87) and healthy controls (OR = 3.19, 95%CI: 1.38-7.36). Liang *et al*[[124](#_ENREF_124)] showed a similar prevalence of factor V Leiden in IBD patients and the general population (summary OR = 1.13, 95%CI: 0.87–1.46). Of note, the factor V Leiden mutation was associated with a signiﬁcantly higher risk of thromboembolism in IBD patients (summary OR = 5.30, 95%CI: 2.25–12.48)[[124](#_ENREF_124)].

The prothrombin G20210A mutation leads to greater prothrombin plasma levels (heterozygous carriers have approximately 30% higher PT levels than healthy controls) and increases the risk of VTE approximately threefold[[122](#_ENREF_122)]. There is no difference in the prevalence of the prothrombin G20210A mutation between IBD patients and normal controls[[110](#_ENREF_110), [120](#_ENREF_120)], between IBD patients with thrombosis and non-IBD patients with thrombosis[[6](#_ENREF_6), [102](#_ENREF_102)] or between IBD patients with and without thrombosis[[102](#_ENREF_102), [104](#_ENREF_104)]. Protein C, protein S and antithrombin III deficiencies also have no increased prevalence among patients with IBD, regardless of whether they have had a VTE[[52](#_ENREF_52), [125-127](#_ENREF_125)].

The factor XIII val34leu mutation is associated with a greater FXIII activation rate and leads to a 20-40% reduction of the risk of VTE for homozygous carriers[[111](#_ENREF_111), [121](#_ENREF_121)]. A slightly greater prevalence of factor XIII (val34leu) mutation carriers in CD was found in a recent population-based study[[109](#_ENREF_109)], but this prevalence could not explain the greater risk of VTE in CD. Available data suggest that there is no difference in the prevalence of homozygous carriers of the factor XIII val34leu mutation between IBD patients and healthy controls[[111](#_ENREF_111), [116](#_ENREF_116), [121](#_ENREF_121)]. Finally, the prevalence of the factor XIII val34leu mutation was similar in thrombotic IBD patients and non-IBD thrombotic patients[[104](#_ENREF_104)].

The MTHFR C677T mutation leads to a 25% increase in homocysteine plasma levels in homozygous carriers[[128](#_ENREF_128)]. The effect of the MTHFR C677T mutation on the risk of VTE varies among studies, and a recent meta-analysis found a weak effect (20% risk increase)[[128](#_ENREF_128)]. The prevalence of the MTHFR C677T mutation in IBD has shown discordant results, most likely because of regional and ethnic variations in the prevalence of this polymorphism in the general population. The allelic frequency of MTHFR C677T has been reported to be higher in IBD patients than in the reference population[[119](#_ENREF_119)]. In a recent population-based case-control study, some differences were observed between patients with IBD and healthy controls (with a decreased number of mutant allele carriers in UC); however, these differences did not explain the excess risk of thrombosis[[109](#_ENREF_109)]. No difference in the prevalence of homozygous carriers of the MTHFR C677T mutation was found between the IBD patients and healthy controls in most studies[[102](#_ENREF_102), [104](#_ENREF_104), [109](#_ENREF_109), [110](#_ENREF_110), [115](#_ENREF_115), [116](#_ENREF_116), [118](#_ENREF_118), [119](#_ENREF_119)]. The prevalence of C677T homozygosity between IBD thrombotic patients and non-IBD thrombotic patients showed no significant difference[[102](#_ENREF_102), [104](#_ENREF_104)].

Several studies have demonstrated that the PAI-1 (4G) homozygosity is associated with enhanced PAI-1 expression[[129](#_ENREF_129)] and contributes as an additional risk factor towards the development of VTE[[130](#_ENREF_130)]. However, the evidence regarding the relationship between an elevated PAI-1 plasma level or PAI-1 4G polymorphism and the risk of VTE is rather conflicting. The allelic frequency of PAI-1 4G has been reported as being higher in IBD patients than in the reference population[[119](#_ENREF_119)]. Moreover, a recent study showed a significantly higher allelic frequency of PAI-1 4G in IBD patients with vascular complications compared with IBD patients and healthy controls[[104](#_ENREF_104)]. No difference in the prevalence of homozygous carriers of the PAI-1 4G mutation was found between IBD patients and healthy controls in most studies[[104](#_ENREF_104), [116](#_ENREF_116), [119](#_ENREF_119)]. The prevalence of this genotype does not differ in thrombotic IBD patients compared with non-IBD thrombotic patients[[104](#_ENREF_104)].

As in the general population, more than one thrombotic defect can occur among IBD patients with inherited thrombophilia, particularly factor V Leiden[[104](#_ENREF_104), [119](#_ENREF_119)]. A higher prevalence of the carriage of two or more thrombogenic polymorphisms has been found in IBD patients compared with the reference population[[119](#_ENREF_119)], but no significant difference has been found between thrombotic and non-thrombotic IBD patients[[104](#_ENREF_104)].

Taken together, these data show that genetic risk factors are generally not found more often in IBD patients than in others, suggesting that genetics does not explain the greater risk of VTE in CD and UC. However, when genetic risk factors occur, patients with IBD (compared with healthy controls) are more likely to suffer thromboembolic complications, suggesting that hereditary thrombophilia and inflammation-associated thrombogenicity have at least an additive effect for the risk of VTE in IBD.

**PHARMACOLOGICAL EFFECT ON RISK FACTORS**

Almost all drugs used in the treatment of IBD have been associated with abnormalities in the haemostatic system in experimental and clinical studies. Corticosteroids have been associated with both hypo- and hypercoagulating alterations[[131](#_ENREF_131), [132](#_ENREF_132)]. A meta-analysis demonstrated that dexamethasone-based chemotherapy was a risk for VTE in patients with multiple myeloma[[133](#_ENREF_133)]. Furthermore, in a large cohort of surgical IBD patients, the use of steroids was identified as a potentially modifiable risk factor for postoperative VTE in IBD patients[[24](#_ENREF_24)]. Studies of platelets from IBD patients treated with 5-aminosalicylic acid (5-ASA) agents have shown conflicting results. *In vitro*, 5-ASA significantly reduced both spontaneous and thrombin-induced platelet activation[[134](#_ENREF_134)]. In vivo, platelets from IBD patients taking 5-ASA have decreased expression levels of P-selectin, a surface marker for platelet activation[[134](#_ENREF_134)], and lower plasma levels of RANTES (Regulated upon Activation Normal T-cell Expressed and Secreted), a prothrombotic platelet cytokine[[135](#_ENREF_135)]. In contrast to these findings, a study of six patients with IBD (four with UC and two with CD) treated with 5-ASA showed no changes in platelet aggregation or fibrinolytic activity[[136](#_ENREF_136)]. Sulfasalazine inhibits dihydrofolate reductase leading to folate deficiency, which is a cause of hyperhomocysteinaemia (acquired thrombophilia; see below). Plasma homocysteinaemia levels have been reported to be significantly increased in patients with ankylosing spondylitis under sulfasalazine therapy[[137](#_ENREF_137)].

Azathioprine has been shown to inhibit platelet aggregation *in vitro*[[138](#_ENREF_138)]. IBD patients taking thiopurines experienced fewer PLAs than patients who were not taking them[[69](#_ENREF_69)]. The *in vitro* data suggest an antithrombotic effect from azathioprine and 6-mercaptopurine. Methotrexate, a folate antagonist, is a well-established contributor to hyperhomocysteinaemia (which is associated with thrombosis risk) when used in patients with rheumatoid arthritis[[139](#_ENREF_139)]. Nonetheless, no study associating methotrexate with hyperhomocysteinaemia is available for IBD. Cyclosporine has been associated with thrombogenicity *in vitro* and in vivo. *In vitro* studies showed an increased platelet aggregation[[138](#_ENREF_138)] and activation of endothelial cells[[140](#_ENREF_140)] induced by cyclosporine. Cyclosporine has also been associated with impaired fibrinolysis through a decrease in PAI-1 activity[[141](#_ENREF_141)]. The *in vitro* thrombogenicity of cyclosporine has been confirmed in vivo by several studies showing thrombotic events in patients taking cyclosporine[[142](#_ENREF_142)].

Infliximab, an antibody against anti-TNF-α, may decrease platelet activity through the downregulation of the CD40/CD40L pathway in the mucosal microcirculation[[76](#_ENREF_76)]. Additionally, in patients with active rheumatoid arthritis, infliximab treatment has been shown to normalise the disease-associated impairment of the coagulation and fibrinolytic systems by decreasing the levels of prothrombin F1+2 and D-dimer[[143](#_ENREF_143)], t-PA antigen, PAI-1 antigen and PAI-1 activity[[144](#_ENREF_144)]. Finally, infliximab induced a significant decrease in the amounts of circulating microparticles in IBD patients[[49](#_ENREF_49)]. Despite these potential anticoagulant effects of the TNF-α blockade, there are also case reports of thrombosis at several sites, such as the retinal vein, in patients under anti-TNF-α therapy[[145](#_ENREF_145)]. Moreover, the prothrombotic effects of anti-TNF-α therapy may be mediated by antiphospholipid antibodies (acquired thrombophilia) as anti-TNF-α therapy has been associated with the development of APLA[[87](#_ENREF_87), [88](#_ENREF_88)]. Nonetheless, a recent prospective observational cohort study of biological safety in patients with rheumatoid arthritis showed that VTE events are not increased in patients with rheumatoid arthritis who are treated with anti-TNF therapy[[146](#_ENREF_146)].

**CONCLUSION**

In IBD, there is an increased risk of thromboembolic events due to inflammation, nutritional deficiencies, hospitalisations, surgery and inherited prothrombotic factors. Moreover, beyond an increased risk, VTE may have clinical specificities in IBD. There is evidence that subjects with IBD experience the first episode of VTE early in life[[6](#_ENREF_6)]. In IBD, the RR of VTE is inversely correlated with age (i.e., younger IBD patients have a higher RR of VTE); nevertheless, the actual incidence increases with age[[8](#_ENREF_8), [11](#_ENREF_11), [13](#_ENREF_13), [21](#_ENREF_21)]. The rate of recurrent VTE in the five years after the discontinuation of anticoagulation therapy is also increased in IBD [adjusted RR (aRR) = 2.5, 95%CI: 1.4–4.2][[16](#_ENREF_16)]. Even with continued prophylaxis for VTE, the risk of recurrence of VTE in IBD patients has been reported to be 13%[[17](#_ENREF_17)]. Low molecular weight heparin (LMWH) has been shown to be less effective in preventing DVT in hospitalised subjects undergoing surgery for IBD than in patients with non-IBD conditions, including colorectal cancer and diverticular disease (aOR = 5.9, 95%CI: 0.9–39.7, for UC and DVT postoperatively)[[147](#_ENREF_147)]. Importantly, VTE appears to carry a poorer prognostic outcome for patients with IBD than for the general population. In a hospitalised cohort, the rate of VTE was not only higher in IBD subjects than in the controls, but the admissions for IBD subjects were also longer (11.7 *vs* 6.1 days; *P <* 0.0001) and were associated with higher costs ($47 515 *vs* $21 499; *P <* 0.0001) and higher mortality (aOR = 2.5, 95%CI: 1.83–3.43)[[12](#_ENREF_12)].

Therefore, clinicians should be aware of these risks so that adequate prophylactic actions can be taken in all IBD patients with flares, particularly in patients who are hospitalised, submitted to surgery or undergoing treatment.

**REFERENCES**

1 **Bargen J**, Barker NW. EXtensive arterial and venous thrombosis complicating chronic ulcerative colitis. *Arch Intern Med* 1936; **58**: 17-31 [DOI: 10.1001/archinte.1936.00170110025002]

2 **Murthy SK**, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. *Am J Gastroenterol* 2011; **106**: 713-718 [PMID: 21407182 DOI: 10.1038/ajg.2011.53]

3 **Yuhara H**, Steinmaus C, Corley D, Koike J, Igarashi M, Suzuki T, Mine T. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2013; **37**: 953-962 [PMID: 23550660 DOI: 10.1111/apt.12294]

4 **Tan VP**, Chung A, Yan BP, Gibson PR. Venous and arterial disease in inflammatory bowel disease. *J Gastroenterol Hepatol* 2013; **28**: 1095-1113 [PMID: 23662785 DOI: 10.1111/jgh.12260]

5 **Tichelaar YI**, Kluin-Nelemans HJ, Meijer K. Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review. *Thromb Haemost* 2012; **107**: 827-837 [PMID: 22437808 DOI: 10.1160/TH11-09-0611]

6 **Grip O**, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. *Scand J Gastroenterol* 2000; **35**: 619-623 [PMID: 10912662]

7 **Talbot RW**, Heppell J, Dozois RR, Beart RW. Vascular complications of inflammatory bowel disease. *Mayo Clin Proc* 1986; **61**: 140-145 [PMID: 3080643]

8 **Bernstein CN**, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. *Thromb Haemost* 2001; **85**: 430-434 [PMID: 11307809]

9 **Miehsler W**, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, Grisar J, Machold K, Scholz S, Vogelsang H, Novacek G. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? *Gut* 2004; **53**: 542-548 [PMID: 15016749]

10 **Huerta C**, Johansson S, Wallander MA, García Rodríguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. *Arch Intern Med* 2007; **167**: 935-943 [PMID: 17502535 DOI: 10.1001/archinte.167.9.935]

11 **Saleh T**, Matta F, Yaekoub AY, Danescu S, Stein PD. Risk of venous thromboembolism with inflammatory bowel disease. *Clin Appl Thromb Hemost* 2011; **17**: 254-258 [PMID: 20211927 DOI: 10.1177/1076029609360528]

12 **Nguyen GC**, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. *Am J Gastroenterol* 2008; **103**: 2272-2280 [PMID: 18684186 DOI: 10.1111/j.1572-0241.2008.02052.x]

13 **Kappelman MD**, Horvath-Puho E, Sandler RS, Rubin DT, Ullman TA, Pedersen L, Baron JA, Sørensen HT. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. *Gut* 2011; **60**: 937-943 [PMID: 21339206 DOI: 10.1136/gut.2010.228585]

14 **Nguyen GC**, Boudreau H, Harris ML, Maxwell CV. Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. *Clin Gastroenterol Hepatol* 2009; **7**: 329-334 [PMID: 19027089 DOI: 10.1016/j.cgh.2008.10.022]

15 **Bröms G**, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H. Complications from inflammatory bowel disease during pregnancy and delivery. *Clin Gastroenterol Hepatol* 2012; **10**: 1246-1252 [PMID: 22922307 DOI: 10.1016/j.cgh.2012.08.018]

16 **Novacek G**, Weltermann A, Sobala A, Tilg H, Petritsch W, Reinisch W, Mayer A, Haas T, Kaser A, Feichtenschlager T, Fuchssteiner H, Knoflach P, Vogelsang H, Miehsler W, Platzer R, Tillinger W, Jaritz B, Schmid A, Blaha B, Dejaco C, Eichinger S. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. *Gastroenterology* 2010; **139**: 779-87, 787.e1 [PMID: 20546736 DOI: 10.1053/j.gastro.2010.05.026]

17 **Solem CA**, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. *Am J Gastroenterol* 2004; **99**: 97-101 [PMID: 14687149]

18 **Jackson LM**, O'Gorman PJ, O'Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. *QJM* 1997; **90**: 183-188 [PMID: 9093595]

19 **Grainge MJ**, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. *Lancet* 2010; **375**: 657-663 [PMID: 20149425 DOI: 10.1016/S0140-6736(09)61963-2]

20 **Bernstein CN**, Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. *Can J Gastroenterol* 2007; **21**: 507-511 [PMID: 17703250]

21 **Sridhar AR**, Parasa S, Navaneethan U, Crowell MD, Olden K. Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients. *J Crohns Colitis* 2011; **5**: 287-294 [PMID: 21683298 DOI: 10.1016/j.crohns.2011.01.011]

22 **Rothberg MB**, Lindenauer PK, Lahti M, Pekow PS, Selker HP. Risk factor model to predict venous thromboembolism in hospitalized medical patients. *J Hosp Med* 2011; **6**: 202-209 [PMID: 21480491 DOI: 10.1002/jhm.888]

23 **Merrill A**, Millham F. Increased risk of postoperative deep vein thrombosis and pulmonary embolism in patients with inflammatory bowel disease: a study of National Surgical Quality Improvement Program patients. *Arch Surg* 2012; **147**: 120-124 [PMID: 22006853 DOI: 10.1001/archsurg.2011.297]

24 **Wallaert JB**, De Martino RR, Marsicovetere PS, Goodney PP, Finlayson SR, Murray JJ, Holubar SD. Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP. *Dis Colon Rectum* 2012; **55**: 1138-1144 [PMID: 23044674 DOI: 10.1097/DCR.0b013e3182698f60]

25 **Papay P**, Miehsler W, Tilg H, Petritsch W, Reinisch W, Mayer A, Haas T, Kaser A, Feichtenschlager T, Fuchssteiner H, Knoflach P, Vogelsang H, Platzer R, Tillinger W, Jaritz B, Schmid A, Blaha B, Dejaco C, Sobala A, Weltermann A, Eichinger S, Novacek G. Clinical presentation of venous thromboembolism in inflammatory bowel disease. *J Crohns Colitis* 2013; **7**: 723-729 [PMID: 23127785 DOI: 10.1016/j.crohns.2012.10.008]

26 **Zöller B**, Li X, Sundquist J, Sundquist K. Autoimmune diseases and venous thromboembolism: a review of the literature. *Am J Cardiovasc Dis* 2012; **2**: 171-183 [PMID: 22937487]

27 **Esmon CT**. The interactions between inflammation and coagulation. *Br J Haematol* 2005; **131**: 417-430 [PMID: 16281932 DOI: 10.1111/j.1365-2141.2005.05753.x]

28 **Zöller B**, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. *Lancet* 2012; **379**: 244-249 [PMID: 22119579 DOI: 10.1016/S0140-6736(11)61306-8]

29 **Lindmark E**, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. *Arterioscler Thromb Vasc Biol* 2000; **20**: 2322-2328 [PMID: 11031222]

30 **Parry GC**, Mackman N. NF-κB Mediated Transcription in Human Monocytic Cells and Endothelial Cells. *Trends Cardiovasc Med* 1998; **8**: 138-142 [PMID: 21235924 DOI: 10.1016/S1050-1738(98)00002-4]

31 **Cermak J**, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. *Blood* 1993; **82**: 513-520 [PMID: 8329706]

32 **Stouthard JM**, Levi M, Hack CE, Veenhof CH, Romijn HA, Sauerwein HP, van der Poll T. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. *Thromb Haemost* 1996; **76**: 738-742 [PMID: 8950783]

33 **van der Poll T**, Büller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJ, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW. Activation of coagulation after administration of tumor necrosis factor to normal subjects. *N Engl J Med* 1990; **322**: 1622-1627 [PMID: 2188129 DOI: 10.1056/NEJM199006073222302]

34 **Fukudome K**, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. *J Biol Chem* 1994; **269**: 26486-26491 [PMID: 7929370]

35 **Klein NJ**, Shennan GI, Heyderman RS, Levin M. Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. *J Cell Sci* 1992; **102** ( Pt 4): 821-832 [PMID: 1429895]

36 **Chen Y**, Wang J, Yao Y, Yuan W, Kong M, Lin Y, Geng D, Nie R. CRP regulates the expression and activity of tissue factor as well as tissue factor pathway inhibitor via NF-kappaB and ERK 1/2 MAPK pathway. *FEBS Lett* 2009; **583**: 2811-2818 [PMID: 19631649 DOI: 10.1016/j.febslet.2009.07.037]

37 **Chen C**, Nan B, Lin P, Yao Q. C-reactive protein increases plasminogen activator inhibitor-1 expression in human endothelial cells. *Thromb Res* 2008; **122**: 125-133 [PMID: 17949793 DOI: 10.1016/j.thromres.2007.09.006]

38 **Singh U**, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. *Arterioscler Thromb Vasc Biol* 2005; **25**: 2216-2221 [PMID: 16123325 DOI: 10.1161/01.ATV.0000183718.62409.ea]

39 **Burstein SA**. Cytokines, platelet production and hemostasis. *Platelets* 1997; **8**: 93-104 [PMID: 20297930 DOI: 10.1080/09537109709169324]

40 **Bhagat K**, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. *Circulation* 1997; **96**: 3042-3047 [PMID: 9386173]

41 **Bisoendial RJ**, Kastelein JJ, Levels JH, Zwaginga JJ, van den Bogaard B, Reitsma PH, Meijers JC, Hartman D, Levi M, Stroes ES. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. *Circ Res* 2005; **96**: 714-716 [PMID: 15774855 DOI: 10.1161/01.RES.0000163015.67711.AB]

42 **Hein TW**, Singh U, Vasquez-Vivar J, Devaraj S, Kuo L, Jialal I. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. *Atherosclerosis* 2009; **206**: 61-68 [PMID: 19268941 DOI: 10.1016/j.atherosclerosis.2009.02.002]

43 **Danese S**, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. *Am J Gastroenterol* 2007; **102**: 174-186 [PMID: 17100967 DOI: 10.1111/j.1572-0241.2006.00943.x]

44 **Scaldaferri F**, Lancellotti S, Pizzoferrato M, De Cristofaro R. Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. *World J Gastroenterol* 2011; **17**: 594-608 [PMID: 21350708 DOI: 10.3748/wjg.v17.i5.594]

45 **Zitomersky NL**, Verhave M, Trenor CC. Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention. *Inflamm Bowel Dis* 2011; **17**: 458-470 [PMID: 20848518 DOI: 10.1002/ibd.21334]

46 **Yoshida H**, Russell J, Senchenkova EY, Almeida Paula LD, Granger DN. Interleukin-1beta mediates the extra-intestinal thrombosis associated with experimental colitis. *Am J Pathol* 2010; **177**: 2774-2781 [PMID: 20971730 DOI: 10.2353/ajpath.2010.100205]

47 **Yoshida H**, Yilmaz CE, Granger DN. Role of tumor necrosis factor-α in the extraintestinal thrombosis associated with colonic inflammation. *Inflamm Bowel Dis* 2011; **17**: 2217-2223 [PMID: 21987296 DOI: 10.1002/ibd.21593]

48 **Larsen TB**, Nielsen JN, Fredholm L, Lund ED, Brandslund I, Munkholm P, Hey H. Platelets and anticoagulant capacity in patients with inflammatory bowel disease. *Pathophysiol Haemost Thromb* ; **32**: 92-96 [PMID: 12214155 DOI: 65082]

49 **Chamouard P**, Desprez D, Hugel B, Kunzelmann C, Gidon-Jeangirard C, Lessard M, Baumann R, Freyssinet JM, Grunebaum L. Circulating cell-derived microparticles in Crohn's disease. *Dig Dis Sci* 2005; **50**: 574-580 [PMID: 15810645]

50 **Palkovits J**, Novacek G, Kollars M, Hron G, Osterode W, Quehenberger P, Kyrle PA, Vogelsang H, Reinisch W, Papay P, Weltermann A. Tissue factor exposing microparticles in inflammatory bowel disease. *J Crohns Colitis* 2013; **7**: 222-229 [PMID: 22705067 DOI: 10.1016/j.crohns.2012.05.016]

51 **Hudson M**, Chitolie A, Hutton RA, Smith MS, Pounder RE, Wakefield AJ. Thrombotic vascular risk factors in inflammatory bowel disease. *Gut* 1996; **38**: 733-737 [PMID: 8707120]

52 **Kume K**, Yamasaki M, Tashiro M, Yoshikawa I, Otsuki M. Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis. *Intern Med* 2007; **46**: 1323-1329 [PMID: 17827828]

53 **Zezos P**, Papaioannou G, Nikolaidis N, Vasiliadis T, Giouleme O, Evgenidis N. Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation. *World J Gastroenterol* 2005; **11**: 7639-7645 [PMID: 16437691]

54 **Smith CJ**, Haire WD, Kaufman SS, Mack DR. Determination of prothrombin activation fragments in young patients with inflammatory bowel disease. *Am J Gastroenterol* 1996; **91**: 1221-1225 [PMID: 8651175]

55 **Chamouard P**, Grunebaum L, Wiesel ML, Frey PL, Wittersheim C, Sapin R, Baumann R, Cazenave JP. Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. *Eur J Gastroenterol Hepatol* 1995; **7**: 1183-1188 [PMID: 8789309]

56 **Lake AM**, Stauffer JQ, Stuart MJ. Hemostatic alterations in inflammatory bowel disease: response to therapy. *Am J Dig Dis* 1978; **23**: 897-902 [PMID: 717349]

57 **Chiarantini E**, Valanzano R, Liotta AA, Cellai AP, Fedi S, Ilari I, Prisco D, Tonelli F, Abbate R. Hemostatic abnormalities in inflammatory bowel disease. *Thromb Res* 1996; **82**: 137-146 [PMID: 9163067]

58 **Souto JC**, Martínez E, Roca M, Mateo J, Pujol J, González D, Fontcuberta J. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. *Dig Dis Sci* 1995; **40**: 1883-1889 [PMID: 7555437]

59 **Saibeni S**, Vecchi M, Valsecchi C, Faioni EM, Razzari C, de Franchis R. Reduced free protein S levels in patients with inflammatory bowel disease: prevalence, clinical relevance, and role of anti-protein S antibodies. *Dig Dis Sci* 2001; **46**: 637-643 [PMID: 11318545]

60 **Jorens PG**, Hermans CR, Haber I, Kockx MM, Vermylen J, Parizel GA. Acquired protein C and S deficiency, inflammatory bowel disease and cerebral arterial thrombosis. *Blut* 1990; **61**: 307-310 [PMID: 2148695]

61 **Koutroubakis IE**, Sfiridaki A, Mouzas IA, Maladaki A, Kapsoritakis A, Roussomoustakaki M, Kouroumalis EA, Manousos ON. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. *Am J Gastroenterol* 2000; **95**: 190-194 [PMID: 10638581 DOI: 10.1111/j.1572-0241.2000.01683.x]

62 **Faioni EM**, Ferrero S, Fontana G, Gianelli U, Ciulla MM, Vecchi M, Saibeni S, Biguzzi E, Cordani N, Franchi F, Bosari S, Cattaneo M. Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease. *Crit Care Med* 2004; **32**: S266-S270 [PMID: 15118529]

63 **Bernhard H**, Deutschmann A, Leschnik B, Novak M, Hauer A, Haidl H, Rosenkranz A, Muntean W. Calibrated automated thrombin generation in paediatric patients with inflammatory bowel disease. *Hamostaseologie* 2009; **29 Suppl 1**: S90-S93 [PMID: 19763358]

64 **Bernhard H**, Deutschmann A, Leschnik B, Schweintzger S, Novak M, Hauer A, Muntean W. Thrombin generation in pediatric patients with Crohn's disease. *Inflamm Bowel Dis* 2011; **17**: 2333-2339 [PMID: 21287673 DOI: 10.1002/ibd.21631]

65 **Chamouard P**, Grunebaum L, Wiesel ML, Sibilia J, Coumaros G, Wittersheim C, Baumann R, Cazenave JP. Significance of diminished factor XIII in Crohn's disease. *Am J Gastroenterol* 1998; **93**: 610-614 [PMID: 9576457 DOI: 10.1111/j.1572-0241.1998.174\_b.x]

66 **de Jong E**, Porte RJ, Knot EA, Verheijen JH, Dees J. Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces. *Gut* 1989; **30**: 188-194 [PMID: 2495239]

67 **Gris JC**, Schved JF, Raffanel C, Dubois A, Aguilar-Martinez P, Arnaud A, Sanchez N, Sarlat C, Balmès JL. Impaired fibrinolytic capacity in patients with inflammatory bowel disease. *Thromb Haemost* 1990; **63**: 472-475 [PMID: 2119529]

68 **Saibeni S**, Bottasso B, Spina L, Bajetta M, Danese S, Gasbarrini A, de Franchis R, Vecchi M. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. *Am J Gastroenterol* 2004; **99**: 1966-1970 [PMID: 15447757 DOI: 10.1111/j.1572-0241.2004.30203.x]

69 **Irving PM**, Macey MG, Shah U, Webb L, Langmead L, Rampton DS. Formation of platelet-leukocyte aggregates in inflammatory bowel disease. *Inflamm Bowel Dis* 2004; **10**: 361-372 [PMID: 15475744]

70 **Collins CE**, Rampton DS, Rogers J, Williams NS. Platelet aggregation and neutrophil sequestration in the mesenteric circulation in inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 1997; **9**: 1213-1217 [PMID: 9471028]

71 **Webberley MJ**, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. *Gut* 1993; **34**: 247-251 [PMID: 8432482]

72 **Danese S**, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, Fiocchi C. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. *Gut* 2003; **52**: 1435-1441 [PMID: 12970136]

73 **Menchén L**, Marín-Jiménez I, Arias-Salgado EG, Fontela T, Hernández-Sampelayo P, Rodríguez MC, Butta NV. Matrix metalloproteinase 9 is involved in Crohn's disease-associated platelet hyperactivation through the release of soluble CD40 ligand. *Gut* 2009; **58**: 920-928 [PMID: 19039088 DOI: 10.1136/gut.2008.150318]

74 **Sawada-Hase N**, Kiyohara T, Miyagawa J, Ueyama H, Nishibayashi H, Murayama Y, Kashihara T, Nakahara M, Miyazaki Y, Kanayama S, Nezu R, Shinomura Y, Matsuzawa Y. An increased number of CD40-high monocytes in patients with Crohn's disease. *Am J Gastroenterol* 2000; **95**: 1516-1523 [PMID: 10894589 DOI: 10.1111/j.1572-0241.2000.01938.x]

75 **Yan SL**, Russell J, Harris NR, Senchenkova EY, Yildirim A, Granger DN. Platelet abnormalities during colonic inflammation. *Inflamm Bowel Dis* 2013; **19**: 1245-1253 [PMID: 23518812 DOI: 10.1097/MIB.0b013e318281f3df]

76 **Danese S**, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, Piqué JM, Panes J, Katz JA, Gasbarrini A, Fiocchi C. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. *J Immunol* 2006; **176**: 2617-2624 [PMID: 16456024]

77 **Papa A**, Scaldaferri F, Danese S, Guglielmo S, Roberto I, Bonizzi M, Mocci G, Felice C, Ricci C, Andrisani G, Fedeli G, Gasbarrini G, Gasbarrini A. Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. *Dig Dis* 2008; **26**: 149-155 [PMID: 18431065 DOI: 10.1159/000116773]

78 **Hatoum OA**, Binion DG, Otterson MF, Gutterman DD. Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. *Gastroenterology* 2003; **125**: 58-69 [PMID: 12851871]

79 **Rafiee P**, Johnson CP, Li MS, Ogawa H, Heidemann J, Fisher PJ, Lamirand TH, Otterson MF, Wilson KT, Binion DG. Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS. Paradoxical proinflammatory effect on the microvascular endothelium. *J Biol Chem* 2002; **277**: 35605-35615 [PMID: 12110686 DOI: 10.1074/jbc.M205826200]

80 **Horowitz S**, Binion DG, Nelson VM, Kanaa Y, Javadi P, Lazarova Z, Andrekopoulos C, Kalyanaraman B, Otterson MF, Rafiee P. Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease. *Am J Physiol Gastrointest Liver Physiol* 2007; **292**: G1323-G1336 [PMID: 17218473 DOI: 10.1152/ajpgi.00499.2006]

81 **Lancellotti S**, De Filippis V, Pozzi N, Peyvandi F, Palla R, Rocca B, Rutella S, Pitocco D, Mannucci PM, De Cristofaro R. Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. *Free Radic Biol Med* 2010; **48**: 446-456 [PMID: 19969076 DOI: 10.1016/j.freeradbiomed.2009.11.020]

82 **Stevens TR**, James JP, Simmonds NJ, McCarthy DA, Laurenson IF, Maddison PJ, Rampton DS. Circulating von Willebrand factor in inflammatory bowel disease. *Gut* 1992; **33**: 502-506 [PMID: 1582595]

83 **Koutroubakis IE**. Role of thrombotic vascular risk factors in inflammatory bowel disease. *Dig Dis* 2000; **18**: 161-167 [PMID: 11279334 DOI: 51389]

84 **Koutroubakis IE**, Petinaki E, Anagnostopoulou E, Kritikos H, Mouzas IA, Kouroumalis EA, Manousos ON. Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. *Dig Dis Sci* 1998; **43**: 2507-2512 [PMID: 9824143]

85 **Hudson M**, Hutton RA, Wakefield AJ, Sawyerr AM, Pounder RE. Evidence for activation of coagulation in Crohn's disease. *Blood Coagul Fibrinolysis* 1992; **3**: 773-778 [PMID: 1489898]

86 **Heneghan MA**, Cleary B, Murray M, O'Gorman TA, McCarthy CF. Activated protein C resistance, thrombophilia, and inflammatory bowel disease. *Dig Dis Sci* 1998; **43**: 1356-1361 [PMID: 9635631]

87 **Nosbaum A**, Goujon C, Fleury B, Guillot I, Nicolas JF, Bérard F. Arterial thrombosis with anti-phospholipid antibodies induced by infliximab. *Eur J Dermatol* 1998; **17**: 546-547 [PMID: 17951145 DOI: 10.1684/ejd.2007.0280]

88 **Vereckei E**, Kriván G, Réti M, Szodoray P, Poór G, Kiss E. Anti-TNF-alpha-induced anti-phospholipid syndrome manifested as necrotizing vasculitis. *Scand J Rheumatol* 2010; **39**: 175-177 [PMID: 20337548 DOI: 10.3109/03009740902832753]

89 **Kang SS**, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. *Am J Hum Genet* 1991; **48**: 536-545 [PMID: 1998339]

90 **McCully KS**. Homocysteine and vascular disease. *Nat Med* 1996; **2**: 386-389 [PMID: 8597939]

91 **Klerk M**, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C--& gt; T polymorphism and risk of coronary heart disease: a meta-analysis. *JAMA* ; **288**: 2023-2031 [PMID: 12387655]

92 **Humphrey LL**, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. *Mayo Clin Proc* 2008; **83**: 1203-1212 [PMID: 18990318 DOI: 10.4065/83.11.1203]

93 **Ray JG**. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. *Arch Intern Med* 1998; **158**: 2101-2106 [PMID: 9801176]

94 **den Heijer M**, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. *Thromb Haemost* 1998; **80**: 874-877 [PMID: 9869152]

95 **Martí-Carvajal AJ**, Solà I, Lathyris D, Karakitsiou DE, Simancas-Racines D. Homocysteine-lowering interventions for preventing cardiovascular events. *Cochrane Database Syst Rev* 2013; **1**: CD006612 [PMID: 23440809 DOI: 10.1002/14651858.CD006612.pub3]

96 **den Heijer M**, Willems HP, Blom HJ, Gerrits WB, Cattaneo M, Eichinger S, Rosendaal FR, Bos GM. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. *Blood* 2007; **109**: 139-144 [PMID: 16960155 DOI: 10.1182/blood-2006-04-014654]

97 **Cattaneo M**, Vecchi M, Zighetti ML, Saibeni S, Martinelli I, Omodei P, Mannucci PM, de Franchis R. High prevalence of hyperchomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications? *Thromb Haemost* 1998; **80**: 542-545 [PMID: 9798965]

98 **Oldenburg B**, Van Tuyl BA, van der Griend R, Fijnheer R, van Berge Henegouwen GP. Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. *Dig Dis Sci* 2005; **50**: 235-240 [PMID: 15745078]

99 **Oussalah A**, Guéant JL, Peyrin-Biroulet L. Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. *Aliment Pharmacol Ther* 2011; **34**: 1173-1184 [PMID: 21967576 DOI: 10.1111/j.1365-2036.2011.04864.x]

100 **Tsiolakidou G**, Koutroubakis IE. Thrombosis and inflammatory bowel disease-the role of genetic risk factors. *World J Gastroenterol* 2008; **14**: 4440-4444 [PMID: 18680221]

101 **Liebman HA**, Kashani N, Sutherland D, McGehee W, Kam AL. The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease. *Gastroenterology* 1998; **115**: 830-834 [PMID: 9753484]

102 **Guédon C**, Le Cam-Duchez V, Lalaude O, Ménard JF, Lerebours E, Borg JY. Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease. *Am J Gastroenterol* 2001; **96**: 1448-1454 [PMID: 11374681 DOI: 10.1111/j.1572-0241.2001.03797.x]

103 **Turri D**, Rosselli M, Simioni P, Tormene D, Grimaudo S, Martorana G, Siragusa S, Mariani G, Cottone M. Factor V Leiden and prothrombin gene mutation in inflammatory bowel disease in a Mediterranean area. *Dig Liver Dis* 2001; **33**: 559-562 [PMID: 11816544]

104 **Koutroubakis IE**, Sfiridaki A, Tsiolakidou G, Theodoropoulou A, Livadiotaki A, Paspatis G, Kouroumalis EA. Genetic risk factors in patients with inflammatory bowel disease and vascular complications: case-control study. *Inflamm Bowel Dis* 2007; **13**: 410-415 [PMID: 17206678 DOI: 10.1002/ibd.20076]

105 **Spina L**, Saibeni S, Battaglioli T, Peyvandi F, de Franchis R, Vecchi M. Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. *Am J Gastroenterol* 2005; **100**: 2036-2041 [PMID: 16128949 DOI: 10.1111/j.1572-0241.2005.42029.x]

106 **Mózsik G**, Nagy Z, Nagy A, Rumi G, Karádi O, Czimmer J, Matus Z, Tóth G, Pár A. Leiden mutation (as genetic) and environmental (retinoids) sequences in the acute and chronic inflammatory and premalignant colon disease in human gastrointestinal tract. *J Physiol Paris* ; **95**: 489-494 [PMID: 11595480]

107 **Over HH**, Ulgen S, Tuğlular T, Tezel A, Avşar E, Geyik G, Başgül S, Sayhan N, Ulusoy N, Kalayci C, Tözün N. Thrombophilia and inflammatory bowel disease: does factor V mutation have a role? *Eur J Gastroenterol Hepatol* 1998; **10**: 827-829 [PMID: 9831402]

108 **Nagy Z**, Nagy A, Karádi O, Figler M, Rumi G, Süto G, Vincze A, Pár A, Mózsik G. Prevalence of the factor V Leiden mutation in human inflammatory bowel disease with different activity. *J Physiol Paris* 2001; **95**: 483-487 [PMID: 11595479]

109 **Bernstein CN**, Sargent M, Vos HL, Rosendaal FR. Mutations in clotting factors and inflammatory bowel disease. *Am J Gastroenterol* 2007; **102**: 338-343 [PMID: 17156138 DOI: 10.1111/j.1572-0241.2006.00974.x]

110 **Vecchi M**, Sacchi E, Saibeni S, Meucci G, Tagliabue L, Duca F, De Franchis R. Inflammatory bowel diseases are not associated with major hereditary conditions predisposing to thrombosis. *Dig Dis Sci* 2000; **45**: 1465-1469 [PMID: 10961731]

111 **Heliö T**, Wartiovaara U, Halme L, Turunen UM, Mikkola H, Palotie A, Färkkilä M, Kontula K. Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease. *Scand J Gastroenterol* 1999; **34**: 170-174 [PMID: 10192195]

112 **Haslam N**, Standen GR, Probert CS. An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 1999; **11**: 1289-1291 [PMID: 10563542]

113 **Papa A**, De Stefano V, Gasbarrini A, Chiusolo P, Cianci R, Casorelli I, Paciaroni K, Cammarota G, Leone G, Gasbarrini G. Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. *Blood Coagul Fibrinolysis* 2000; **11**: 499-503 [PMID: 10937811]

114 **Maher MM**, Soloma SH. Assessment of thrombophilic abnormalities during the active state of inflammatory bowel disease. *Saudi J Gastroenterol* 2008; **14**: 192-197 [PMID: 19568537 DOI: 10.4103/1319-3767.41743]

115 **Yasa MH**, Bolaman Z, Yukselen V, Kadikoylu G, Karaoglul AO, Batun S. Factor V Leiden G1691A, prothrombin G20210A, and MTHFR C677T mutations in Turkish inflammatory bowel disease patients. *Hepatogastroenterology* ; **54**: 1438-1442 [PMID: 17708272]

116 **Yilmaz S**, Bayan K, Tüzün Y, Batun S, Altintaş A. A comprehensive analysis of 12 thrombophilic mutations and related parameters in patients with inflammatory bowel disease: data from Turkey. *J Thromb Thrombolysis* 2006; **22**: 205-212 [PMID: 17111197 DOI: 10.1007/s11239-006-9032-5]

117 **Mahmood A**, Needham J, Prosser J, Mainwaring J, Trebble T, Mahy G, Ramage J. Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 2005; **17**: 739-744 [PMID: 15947551]

118 **Törüner M**, Erkan O, Soykan I, Bozdayi M, Cetinkaya H, Yurdaydin C, Uzunalimoğlu O, Ozden A. Factor V Leiden, prothrombin G20210A and MTHFR gene mutations in inflammatory bowel disease. *Turk J Gastroenterol* 2004; **15**: 250-252 [PMID: 16249980]

119 **Magro F**, Dinis-Ribeiro M, Araújo FM, Pereira P, Fraga MC, Cunha-Ribeiro LM, Tomé-Ribeiro A. High prevalence of combined thrombophilic abnormalities in patients with inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 2003; **15**: 1157-1163 [PMID: 14560147 DOI: 10.1097/01.meg.0000085474.12407.ce]

120 **Bjerregaard LT**, Nederby NJ, Fredholm L, Brandslund I, Munkholm P, Hey H. Hyperhomocysteinaemia, coagulation pathway activation and thrombophilia in patients with inflammatory bowel disease. *Scand J Gastroenterol* 2002; **37**: 62-67 [PMID: 11843038]

121 **Saibeni S**, Vecchi M, Faioni EM, Franchi F, Rondonotti E, Borsi G, de Franchis R. Val34Leu factor XIII polymorphism in Italian patients with inflammatory bowel disease. *Dig Liver Dis* 2003; **35**: 32-36 [PMID: 12725605]

122 **Dahlbäck B**. Advances in understanding pathogenic mechanisms of thrombophilic disorders. *Blood* 2008; **112**: 19-27 [PMID: 18574041 DOI: 10.1182/blood-2008-01-077909]

123 **Zhong M**, Dong XW, Zheng Q, Tong JL, Ran ZH. Factor V Leiden and thrombosis in patients with inflammatory bowel disease (IBD): a meta-analysis. *Thromb Res* 2011; **128**: 403-409 [PMID: 21831411 DOI: 10.1016/j.thromres.2011.07.014]

124 **Liang J**, Wu S, Feng B, Lei S, Luo G, Wang J, Li K, Li X, Xie H, Zhang D, Wang X, Wu K, Miao D, Fan D. Factor V Leiden and inflammatory bowel disease: a systematic review and meta-analysis. *J Gastroenterol* 2011; **46**: 1158-1166 [PMID: 21805067 DOI: 10.1007/s00535-011-0441-7]

125 **Ghosh S**, Mackie MJ, McVerry BA, Galloway M, Ellis A, McKay J. Chronic inflammatory bowel disease, deep-venous thrombosis and antithrombin activity. *Acta Haematol* 1983; **70**: 50-53 [PMID: 6191510]

126 **Yurekli BP**, Aksoy DY, Aybar M, Egesel T, Gurgey A, Hascelik G, Kirazli S, Haznedaroglu IC, Arslan S. The search for a common thrombophilic state during the active state of inflammatory bowel disease. *J Clin Gastroenterol* 2006; **40**: 809-813 [PMID: 17016137 DOI: 10.1097/01.mcg.0000225603.33481.56]

127 **van Bodegraven AA**, Schoorl M, Linskens RK, Bartels PC, Tuynman HA. Persistent activation of coagulation and fibrinolysis after treatment of active ulcerative colitis. *Eur J Gastroenterol Hepatol* 2002; **14**: 413-418 [PMID: 11943956]

128 **Den Heijer M**, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. *J Thromb Haemost* 2005; **3**: 292-299 [PMID: 15670035 DOI: 10.1111/j.1538-7836.2005.01141.x]

129 **Dawson S**, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. *Arterioscler Thromb* 1991; **11**: 183-190 [PMID: 1670989]

130 **Stegnar M**, Uhrin P, Peternel P, Mavri A, Salobir-Pajnic B, Stare J, Binder BR. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. *Thromb Haemost* 1998; **79**: 975-979 [PMID: 9609232]

131 **Frank RD**, Altenwerth B, Brandenburg VM, Nolden-Koch M, Block F. Effect of intravenous high-dose methylprednisolone on coagulation and fibrinolysis markers. *Thromb Haemost* 2005; **94**: 467-468 [PMID: 16116692]

132 **Pandit HB**, Spillert CR. Effect of methylprednisolone on coagulation. *J Natl Med Assoc* 1999; **91**: 453-456 [PMID: 12656434]

133 **El Accaoui RN**, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. A meta-analysis. *Thromb Haemost* 2007; **97**: 1031-1036 [PMID: 17549307]

134 **Carty E**, MacEy M, Rampton DS. Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease. *Aliment Pharmacol Ther* 2000; **14**: 1169-1179 [PMID: 10971234]

135 **Fägerstam JP**, Whiss PA, Ström M, Andersson RG. Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease. *Inflamm Res* 2000; **49**: 466-472 [PMID: 11071121]

136 **Winther K**, Bondesen S, Hansen SH, Hvidberg EF. Lack of effect of 5-aminosalicylic acid on platelet aggregation and fibrinolytic activity in vivo and in vitro. *Eur J Clin Pharmacol* 1987; **33**: 419-422 [PMID: 2965019]

137 **Wei JC**, Jan MS, Yu CT, Huang YC, Yang CC, Tsou HK, Lee HS, Chou CT, Tsay G, Chou MC. Plasma homocysteine status in patients with ankylosing spondylitis. *Clin Rheumatol* 2007; **26**: 739-742 [PMID: 17024318 DOI: 10.1007/s10067-006-0396-x]

138 **Małyszko J**, Małyszko JS, Takada A, Myśliwiec M. Effects of immunosuppressive drugs on platelet aggregation in vitro. *Ann Transplant* 2002; **7**: 55-68 [PMID: 12221905]

139 **van Ede AE**, Laan RF, Blom HJ, Boers GH, Haagsma CJ, Thomas CM, De Boo TM, van de Putte LB. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. *Rheumatology (Oxford)* 2002; **41**: 658-665 [PMID: 12048292]

140 **Bombeli T**, Müller M, Straub PW, Haeberli A. Cyclosporine-induced detachment of vascular endothelial cells initiates the intrinsic coagulation system in plasma and whole blood. *J Lab Clin Med* 1996; **127**: 621-634 [PMID: 8648267]

141 **van den Dorpel MA**, Veld AJ, Levi M, ten Cate JW, Weimar W. Beneficial effects of conversion from cyclosporine to azathioprine on fibrinolysis in renal transplant recipients. *Arterioscler Thromb Vasc Biol* 1999; **19**: 1555-1558 [PMID: 10364089]

142 **Al-Shekhlee A**, Oghlakian G, Katirji B. A case of cyclosporine-induced dural sinus thrombosis. *J Thromb Haemost* 2005; **3**: 1327-1328 [PMID: 15946232 DOI: 10.1111/j.1538-7836.2005.01387.x]

143 **Ingegnoli F**, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, Meroni PL, Cugno M. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. *J Autoimmun* 2008; **31**: 175-179 [PMID: 18707846 DOI: 10.1016/j.jaut.2008.07.002]

144 **Ingegnoli F**, Fantini F, Griffini S, Soldi A, Meroni PL, Cugno M. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. *Clin Exp Rheumatol* ; **28**: 254-257 [PMID: 20483049]

145 **Puli SR**, Benage DD. Retinal vein thrombosis after infliximab (Remicade) treatment for Crohn's disease. *Am J Gastroenterol* 2003; **98**: 939-940 [PMID: 12738486 DOI: 10.1111/j.1572-0241.2003.07368.x]

146 **Davies R**, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. *Ann Rheum Dis* 2011; **70**: 1831-1834 [PMID: 21784722 DOI: 10.1136/ard.2011.153536]

147 **Scarpa M**, Pilon F, Pengo V, Romanato G, Ruffolo C, Erroi F, Elisa B, Frego M, Ossi E, Manzato E, Angriman I. Deep venous thrombosis after surgery for inflammatory bowel disease: is standard dose low molecular weight heparin prophylaxis enough? *World J Surg* 2010; **34**: 1629-1636 [PMID: 20177681 DOI: 10.1007/s00268-010-0490-8]

148 **Ha C**, Magowan S, Accortt NA, Chen J, Stone CD. Risk of arterial thrombotic events in inflammatory bowel disease. *Am J Gastroenterol* 2009; **104**: 1445-1451 [PMID: 19491858 DOI: 10.1038/ajg.2009.81]

**P-Reviewers:** **Arias M,** Mezalek ZT,Ren J  **S-Editor:** Wen LL  **L-Editor:**  **E-Editor:**

**Table 1 Risk of venous thrombosis in** **inflammatory bowel disease patients relative to non-inflammatory bowel disease patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author, year, country** | **Design** | **Population** | **Risk measure (95% CI)** | **Controlled variables** |
| **IBD** | **Controls** |
| Grip *et al*[[6](#_ENREF_6)], 2000Sweden | Retrospective cohort studyInpatientsRecords from 2 university hospitals  | 1253 patients | 387 (significant age differences between the IBDcohort and controls) | **Incidence rate of VTE**1.5/1000 IBD per year (comparable to the background population) |  |
| Bernstein *et al*[[8](#_ENREF_8)], 2001Canada  | Retrospective cohort studyInpatientsManitoba Health administrative1984–1997 | 5529 patients  | approximately 55000 year, age, gender and postal area of residence matched members of the general population  | **DVT**RR 4.7 (3.5-6.3) CDRR 2.8 (2.1-3.7) UC**PE**RR 2.9 (1.8-4.7) CDRR 3.6 (2.5-5.2) UC |  |
| Mieshler *et al*[[9](#_ENREF_9)], 2004Austria | Retrospective cohort studyOutpatients and inpatientsThree outpatient clinics of Division ofGastroenterology and Hepatology | 618 patients  | 707 age and gender matched controls  | **Incidence rate of VTE**6.2% IBD1.6% Controls**VTE**aOR 3.6 (1.7-7.8) IBD | Operation, injuries, oral contraceptive use, pregnancy, body mass index and smoking |
| Bernstein *et al*[[20](#_ENREF_20)], 2007Canada | Retrospective cohort studyInpatientsThe Statistics Canada’s Health PersonOriented Information database1994-2004 | ~22 000 to 25 000 patients | ~2.5 to 3.2 million age and gender matched controls | **VTE**≥ 50 years oldRR 1.3 (1.23–1.37) IBD< 50 years oldRR 1.57 (1.42–1.72) IBD |  |
| Huerta *et al*[[10](#_ENREF_10)], 2007United Kingdom  | Prospective cohort study with nested case-control analysisOutpatients and inpatients General Practice Research Database – GPRD1994-2000 | 6550 patients  | 10 000 age, gender and year matched controls | **VTE**OR 1.84 (1.29–2.63) IBD |  |
| Nguyen *et al*[[12](#_ENREF_12)], 2008United States | Retrospective cohort studyInpatientsNationwide Inpatient Sample1998-2004 | 116 842 patients (73 197 CD and 43 645 UC patients)  | 522 703 controls | **VTE**aOR 1.48 (1.35-1.62) DCaOR 1.85 (1.70-2.01) UC | Age, gender, calendar year, health insurance payer, comorbidity, presence of IBD relatedsurgery, geographic location, and hospital characteristics |
| Ha *et al*[[148](#_ENREF_148)], 2009United States | Retrospective cohort studyOutpatients and inpatients MarketScan Commercial Claims and Encounters database - Thomson Reuters 2001-2006 | 17 487 patients (7 480 CD and 9 968 UC patients)  | 69 948 age, gender and index date matched controls | **PVT** aHR 6.2 (*P <* 0.05) IBD**DVT** aHR 2.3 (*P <* 0.0001) IBD**PE** aHR 1.7 (*P <* 0.001) IBD | Hypertension, diabetes, hyperlipidemia, and, in women, the use of contraceptives |
| Nguyen *et al*[[14](#_ENREF_14)], 2009United States | Retrospective cohort studyPregnant hospitalized women Nationwide Inpatient Sample 2005 | 3740 patients (2372 CD and 1368 UC patients)  | 4.21 million pregnant women | **VTE**aOR 6.12 (2.91-12.9) CDaOR 8.44 (3.71-19.2) UC | Maternal age, race/ethnicity, medianneighbourhood income, comorbidity, healthinsurance, geographical region, hospital locationand teaching status and caesarean delivery |
| Grainge *et al*[[19](#_ENREF_19)], 2010United Kingdom | Retrospective cohort studyOutpatients and inpatients General Practice Research Database 1987-2001 | 13 756 patients (4835 CD and 6765 UC patients)  | 71 672 age, gender, and general practice matched controls | **VTE**aHR 3.4 (2.7-4.3) IBD  | Age, sex, body-mass index, smoking, cancer diagnosis and history of pulmonary embolism or deep vein thrombosis |
| Novacek *et al*[[16](#_ENREF_16)], 2010Austria | Retrospective cohort study Outpatients IBD patients from 14 Austrian centers specializing in the treatment of patients with IBD (2006-2008) and controls patients from 4 centers in Austria (1992-2008)2006-2008 | 86 patients with history of unprovoked VTE  | 1255 controls with unprovoked VTE | **Recurrence 5 years after discontinuation of anticoagulation therapy**aRR 2.5 (1.4 – 4.2) IBD | Age, gender, factor V Leiden, prothrombin G20210A mutation, high factor VIII (>234 IU/dL), duration of anticoagulation and body mass index |
| Scarpa *et al*[[147](#_ENREF_147)], 2010Italy | Prospective case-control studyHospitalized patients who had major colo-rectal surgeryPatients admitted for colorectalsurgery in the institute of Clinica Chirurgica I of the Universityof Padova (Italy)2004-2006 | 323 patients  | 432 controls | **Incidence rate of VTE in surgical IBD patients *vs* surgical non IBD patients (both with prophylactic therapy)**1.9% *vs* 0%**VTE with prophylactic therapy**OR 5.9 (0.9–39.7) UC |  |
| Kappelman *et al*[[13](#_ENREF_13)], 2011Denmark | Retrospective cohort study and nested case-control study Danish National Patient Registry1980-2007 | 49 799 patients (14 211 CD and 35 229 UC patients) | 477 504 age and gender matched members of the general population | **All VTE**HR 2.0 (1.8-2.1) IBD HR 2.2 (2.0-2.5) CD HR 1.9 (1.8-2.0) UC **Unprovoked VTE**HR 1.6 (1.5-1.8) IBD HR 2.0 (1.6-2.5) CD HR 1.5 (1.4-1.7) UC aOR 1.7 (1.3-2.2) IBD | Comorbidities and medications |
| Merril *et al*[[23](#_ENREF_23)], 2011United States | Retrospective cohort studySurgical patientsNational Surgical Quality Improvement Program 2008 | 2249 patients  | 269 119 patients without IBD who were hospitalized and underwent surgery | **VTE**aOR 2.03 (1.52-2.70) IBD | Age, gender, race/ethnicity, admitted from home,smoker, BMI>30, medical history, clinical factor |
| Rothberg *et al*[[22](#_ENREF_22)], 2011United States | Retrospective cohort studyInpatients374 US hospitals2004-2005 | 814 patients  | 241924 controls | **VTE**aOR 3.11 (1.59–6.08) IBD | Age, gender, VTE prophylaxis, length of stay≥ 6 days, primary diagnosis, comorbidities, cancer and treatments |
| Saleh *et al*[[11](#_ENREF_11)], 2011United States | Retrospective cohort studyInpatientsNational Hospital Discharge Survey1979 - 2005 | 2 932 000 patients (1 803 000 CD and 1 129 000 UC patients)  | 918 570 000 age, gender matched controls | **VTE**HR 1.08 (1.06-1.09) CD HR 1.64 (1.62-1.66) UC |  |
| Shridhar *et al*[[21](#_ENREF_21)], 2011United States | Cross-sectional studyInpatientsNationwide Inpatient Sample 2010 | 148 229 patients  | 17 261 952 controls | **VTE (DVT, PE and/or PVT)**aOR 1.38 (1.25-1.53) IBD | Hypertension, diabetes mellitus and hyperlipidemia |
| Bröms *et al*[[15](#_ENREF_15)], 2012Sweden | Retrospective cohort studyPregnant womenMedical, Patient, and Prescribed DrugRegisters of all residents in Sweden2006 - 2009 | 1996 patients (787 CD and 1209 UC patients) who gave birth to a single infant | 10 773 women without IBD who gave birth to a single infant | **VTE**aRR 2.65 (0.65–10.1) CD (with inactive disease)aRR 3.78 (1.52–9.38) UC | Age, parity, smoking, body mass index and comorbidities  |

IBD: Inflammatory bowel disease; CD: Crohn’s disease; UC: Ulcerative colitis; VTE: Venous thrombosis; DVT: Deep venous thrombosis; PE: Pulmonary emboli; PVT: Portal vein thrombosis; aRR: Adjusted relative risk; aOR: Adjusted odds ratio; aHR: Adjusted hazard ratio.

**Table 2 Prothrombotic risk factors and abnormalities associated with inflammatory bowel disease**

|  |
| --- |
| **Acquired prothrombotic risk factors** |
| Infection or inflammation, Previous thromboembolism, Age, Smoking, Malignancy, Central venous catheter, Surgery, Trauma, Immobilization , Pregnancy, Drugs (Oral contraceptives, Steroids), Antiphospholipid antibody syndrome, Hyperhomocysteinemia, Fluid depletion |
| **Genetic prothrombotic risk factors** |
| Factor V Leiden, Prothrombin mutation, Deficiency of protein C, Deficiency of protein S, Deficiency of antithrombin, PAI-1 mutation, factor XII mutation and MTHFR mutation |
| **Abnormalities of coagulation** |
| ↑ TF, Factors VII, FXII, FXI, FX and FV, prothrombin and fibrinogen↓ AT, protein C, protein S, EPCR, TM and TFPI↑ prothrombin fragment 1+2, TAT complexes, fibrinopetide A and fibrinopeptide B↓ Factor XIII |
| **Abnormalities of fibrinolysis** |
| ↓ t-PA↑ PAI-1 and TAFI↑ D-dimer |
| **Abnormalities of platelets** |
| ↑ number, activation (CD40L and P-selectin) and aggregation |
| **Abnormalities of endothelium** |
| ↓ NO↑ vWF |

PAI-1: Plasminogen activator inhibitor 1; MTHFR: Methylenetetrahydrofolate reductase; TF: Tissue factor; AT: Antithrombin; EPCR: Endothelial cell protein C receptor; TM: Thrombomodulin; TFPI: Tissue factor-pathway inhibitor; TAT: Thrombin-antihrombin; t-PA: Tissue plasminogen activator; TAFI: Thrombin-activatable fibrinolysis inhibitor; CD40L: CD40 ligand; vWF: Von Willebrand factor.

**Table 3 Controlled studies on the prevalence of inherited thrombophilias in inflammatory bowel disease**

|  |  |  |
| --- | --- | --- |
| **Author, year, country** | **Compared groups** | **Results** |
| **Mutation1** | **CD** | **UC** | **IBD** | **IBD-VTE** | **HC** | **C-VTE** | **Significance** |
| Liebman *et al*[[101](#_ENREF_101)], 1998United States | 11 IBD-VTE patients and 51 IBD patients without VTE | Factor V Leiden  |  |  | 4% | 36% |  |  | Significant difference (OR = 14.00, 95%CI:1.55-169.25) |
| Over *et al*[[107](#_ENREF_107)], 1998Turkey | 63 IBD patients (20 CD and 43 UC patients) and 36 HC | Factor V Leiden  | 50% | 20% |  |  | 11% |  | Significant difference for CD *vs* HC (OR = 6.5, 95% CI = 1.3-18.0)  |
| Haslam *et al*[[112](#_ENREF_112)], 1999United Kingdom | 54 IBD patients (30 CD and 24 UC patients) and 55 HC | Factor V Leiden |  |  | 9.3% |  | 3.6% |  | Difference not significant  |
| Heliö *et al*[[111](#_ENREF_111)], 1999Finland | 563 IBD patients (235 CD and 328 UC patients) and 142 HC | Factor V Leiden | 3.4% | 5.2% | 4.5% |  | 2.1% |  | Differences not significant  |
| Factor XIII mutation | 5.0% | 6.1% | 5.7% |  | 3.3% |  | Differences not significant  |
| Grip *et al*[[6](#_ENREF_6)], 2000Sweden | 16 IBD-VTE patients, 99 C-VTE and 288 HC | Factor V Leiden |  |  |  | 27% | 11% | 28% | Significant difference for IBD-VTE *vs* HC (OR = 3.0, 95% CI = 0.8-11.9) |
| Prothrombin mutation |  |  |  | 0% | 1.8% | 7.1% | Differences not significant  |
| Koutroubakis *et al*[[61](#_ENREF_61)], 2000Greece | 84 IBD patients (36 CD and 48 UC patients) and 61 HC | Factor V Leiden |  |  | 8.3% |  | 4.9% |  | Difference not significant  |
| Papa *et al*[[113](#_ENREF_113)], 2000Italy | 52 IBD patients (19 CD and 33 UC patients) and 156 HC | Factor V Leiden |  |  | 1.9% |  | 1.9% |  | Difference not significant  |
| Prothrombin mutation |  |  | 1.9% |  | 2.6% |  | Difference not significant  |
| Vecchi *et al*[[110](#_ENREF_110)], 2000Italy | 102 IBD (51 CD and 51 UC patients) and 204 HC | Factor V Leiden |  |  | 1.5% |  | 1.2% |  | Difference not significant  |
| Prothrombin mutation |  |  | 1.1% |  | 0.7% |  | Difference not significant  |
| MTHFR mutation |  |  | 41.1% |  | 47.4% |  | Difference not significant  |
| Guédon *et al*[[102](#_ENREF_102)], 2001France | 15 IBD-VTE, 58 IBD patients without VTE, 110 C- VTE and 84 HC | Factor V Leiden |  |  | 0% | 14.3% | 3.6% | 15.5% | Significant difference for IBD-VTE *vs* IBD (*P <* 0.05) |
| Prothrombin mutation |  |  | 1.7% | 14.3% | 3.6 | 11.8% | Differences not significant  |
| MTHFR mutation |  |  | 0% | 0% | 1.2% | 0.9% | Differences not significant  |
| Mozski *et al*[[106](#_ENREF_106)], 2001Hungary | 84 IBD patients (49 CD and 35 UC patients) and 57 HC | Factor V Leiden | 14.3% | 27.5% |  |  | 5.3% |  | Significant difference for CD and UC *vs* HC (*P <* 0.05) |
| Nagy *et al*[[108](#_ENREF_108)], 2001Hungary | 78 IBD patients (49 CD and 29 UC patients) and 57 HC | Factor V Leiden | 14.3% | 27.6% |  |  | 5.3% |  | Significant difference for CD and UC *vs* HC (*P <* 0.05) |
| Turri *et al*[[103](#_ENREF_103)], 2001Italy | 18 IBD patients with arterial or venous thrombosis, 45 IBD patients without thromboembolic events and 100 HC | Factor V Leiden |  |  | 2.2% | 0% | 5% |  | Differences not significant  |
| Prothrombin mutation |  |  | 0% | 0% | 2% |  | Differences not significant  |
| Bjerregaard *et al*[[120](#_ENREF_120)], 2002Denmark | 106 IBD patients and 4188 HC | Factor V Leiden |  |  | 5.7% |  | 6.7% |  | Difference not significant  |
| Prothrombin mutation |  |  |  |  |  |  | Difference not significant  |
| Magro *et al*[[119](#_ENREF_119)], 2003Portugal | 116 IBD patients (74 CD and 42 UC) and 141 healthy controls | Factor V Leiden | 7% | 2% |  |  | 1% |  | Differences not significant  |
| G20210A Prothrombin | 4% | 0% |  |  | 3% |  | Differences not significant  |
| MTHFR mutation | 14% | 12% |  |  | 10% |  | Differences not significant  |
| PAI-1 mutation | 11% | 14% |  |  | 24% |  | Differences not significant  |
| Saibeni *et al*[[121](#_ENREF_121)], 2003Italy | 152 IBD patients (62 CD and 90 UC patients) and 130 HC | Factor XIII mutation  |  |  | 5.3% |  | 5.4% |  | Difference not significant  |
| Törüner *et al*[[118](#_ENREF_118)], 2004Turkey | 62 IBD patients (28 CD and 32 UC patients) and 80 HC | Factor V Leiden |  |  | 3.2% |  | 6.3% |  | Difference not significant  |
| Prothrombin mutation |  |  | 0% |  | 2.5% |  | Difference not significant  |
| MTHFR mutation |  |  | 11.3% |  | 6.3% |  | Difference not significant  |
| Mahmood *et al*[[117](#_ENREF_117)], 2005United Kingdom | 68 IBD patients (31 CD and 37 UC patients) and 30 HC | Factor V Leiden | 0% | 1.5% | 1.5% |  | 0% |  | Differences not significant  |
| Prothrombin mutation | 0% | 1.5% | 1.5% |  | 0% |  | Differences not significant  |
| Oldenburg *et al*[[98](#_ENREF_98)], 2005 Netherlands | 22 IBD-VTE patients and 23 IBD patients without VTE | Factor V Leiden |  |  | 0% | 20% |  |  | Difference not significant  |
| Prothrombin mutation |  |  | 8.7% | 4.5% |  |  | Difference not significant  |
| Spina *et al*[[105](#_ENREF_105)], 2005Italy | 47 IBD-VTE patients and 94 C-VTE | Factor V Leiden |  |  |  | 2.1% |  | 13.8% | Significant difference for C-VTE *vs* IBD-VTE (*P <* 0.05) |
| Prohrombin mutation |  |  |  | 8.5% |  | 12.8% | Difference not significant |
| Yilmaz *et al*[[116](#_ENREF_116)], 2006Turkey | 27 IBD patients and 27 HC | Factor V Leiden |  |  | 6.7% |  | 5% |  | Difference not significant  |
| Prothrombin mutation |  |  | 3.3% |  | 6.7% |  | Difference not significant |
| Factor XIII mutation |  |  | 5% |  | 0% |  | Difference not significant  |
| MTHFR mutation |  |  | 3.3% |  | 0% |  | Difference not significant  |
| PAI-1 mutation |  |  | 11.7% |  | 8.3% |  | Difference not significant  |
| Bernstein *et al*[[109](#_ENREF_109)], 2007Canada | 492 IBD patients (327 CD and 165 UC) and 412 HC | Factor V Leiden | 6.4% | 4.2% |  |  | 6.1% |  | Differences not significant  |
| Prothrombin mutation | 1.8% | 1.2% |  |  | 1.2% |  | Differences not significant  |
| Factor XIII mutation | 8.7% | 7.1% |  |  | 4.3% |  | Significant difference for CD *vs* HC (*P <* 0.05) |
| MTHFR mutation | 12.5% | 9.9% |  |  | 11.7% |  | Differences not significant  |
| Koutroubakis *et al*[[104](#_ENREF_104)], 2007Greece | 30 IBD patients with vascular complications, 60 IBD patients without vascular complications, 30 controls with vascular complications and 54 HC | Factor V Leiden |  |  | 6.7% | 20.0% | 3.7% | 16.7% | Significant difference for IBD-VTE *vs* HC (*P <* 0.05) |
| Prothrombin mutation |  |  | 5.0% | 10.0% | 1.9% | 13.3% | Differences not significant  |
| Factor XIII mutation |  |  | 3.3% | 0% | 1.9% | 0% | Differences not significant  |
| MTHFR mutation |  |  | 11.6% | 6.6% | 7.5% | 13.3% | Differences not significant  |
| PAI-1 mutation |  |  | 20% | 43.3% | 13.0% | 36.7% | Significant difference for IBD-VTE *vs* HC (*P <* 0.05) |
| Yasa *et al*[[115](#_ENREF_115)], 2007Turkey | 27 IBD patients and 47 HC | Factor V Leiden |  |  | 11.1% |  | 4.3% |  | Difference not significant  |
| Prothrombin mutation |  |  | 7.4% |  | 0% |  | Difference not significant  |
| MTHFR mutation |  |  | 14.9% |  | 6.3% |  | Difference not significant  |
| Maher *et al*[[114](#_ENREF_114)], 2010Saudi Arabia | 26 IBD patients (7 CD and 19 UC patients) and 40 HC | Factor V Leiden |  |  | 3.8% |  | 2.5% |  | Difference not significant  |
| Novacek *et al*[[16](#_ENREF_16)], 2010Austria | 102 IBD patients (77 CD and 25 UC) and 102 HC | Factor V Leiden |  |  | 16.1% |  | 26.1% |  | Difference not significant  |
| Prothrombin mutation |  |  | 1.7% |  | 6% |  | Difference not significant  |

VTE: Venous thrombosis; CD: Crohn’s disease; UC: Ulcerative colitis; IBD: Inflammatory bowel disease; IBD-VTE: Inflammatory bowel disease with venous thrombosis; HC: Healthy controls; C-VTE: Controls with venous thrombosis; OR: Odds ratio. 1Presented prevalence data refer to heterozygous and homozygous carrier for FV Leiden and prothrombin mutation and to homozygous carrier for the other mutations.